Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.01) EPS for the quarter, Zacks reports. The firm had revenue of $0.59 million during the quarter.
Guided Therapeutics Price Performance
Guided Therapeutics stock remained flat at $0.23 during trading on Wednesday. The company had a trading volume of 9,496 shares, compared to its average volume of 16,664. The firm has a 50 day simple moving average of $0.34 and a 200 day simple moving average of $0.31. Guided Therapeutics has a 1-year low of $0.06 and a 1-year high of $0.54. The company has a market capitalization of $21.27 million, a P/E ratio of -4.60 and a beta of 0.57.
Guided Therapeutics Company Profile
Guided Therapeutics, Inc is a medical device company focused on the development and commercialization of non‐invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.
The company secured 510(k) clearance from the U.S.
Further Reading
Receive News & Ratings for Guided Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guided Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
